Stocks › TAK
TAKEDA PHARMACEUTICAL CO LTD
TAK·NYSE·
Japan·USD
$21.77
+0.36 (+1.68%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
TAK
TAKEDA PHARMACEUTICAL CO LTD · NYSE
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
TAKS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of TAK by members of U.S. Congress · 21 on record · 3 in the last 12 months
Whale Activity
Position changes in TAK reported for 2026-09-30 by 439 institutional filers
- Increased171
- New56
- Held62
- Decreased82
- Closed39
- No prior filing29
| Filer | Shares | Value | Change |
|---|---|---|---|
| Capital Research Global Investors | 27.0M | $490.3M | increased |
| FMR LLC | 11.0M | $199.6M | increased |
| MORGAN STANLEY | 8.2M | $149.8M | increased |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 7.2M | $131.0M | increased |
| GOLDMAN SACHS GROUP INC | 5.5M | $100.8M | increased |
| BRANDES INVESTMENT PARTNERS, LP | 4.2M | $77.1M | decreased |
| BlackRock, Inc. | 3.9M | $71.6M | increased |
| D. E. Shaw & Co., Inc. | 3.1M | $57.1M | increased |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 3.0M | $54.5M | decreased |
| RENAISSANCE TECHNOLOGIES LLC | 2.3M | $41.7M | decreased |
| Qube Research & Technologies Ltd | 2.2M | $39.2M | decreased |
| JPMORGAN CHASE & CO | 2.0M | $36.3M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by TAK insiders, by quarter · Form 4
Recent Insider Transactions
57 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Platford Giles RichardPresident, IBU | Sale | −55.6K | $20.90 | $1.2M | Nov 4, 2026 | Form 4 ↗ |
| Bitetti Teresa MariePresident, OBU | Sale | −46.6K | $20.89 | $974K | Nov 2, 2026 | Form 4 ↗ |
| Duprey Lauren RusckowskiChief Transformation Officer | Sale | −34.5K | $18.54 | $640K | Sep 14, 2026 | Form 4 ↗ |
| Plump Andrew StewartPresident, R&D · Director | Sale | −116.2K | $18.49 | $2.1M | Sep 2, 2026 | Form 4 ↗ |
| Plump Andrew StewartPresident, R&D · Director | Sale | −19.7K | $18.49 | $363K | Aug 19, 2026 | Form 4 ↗ |
| Greenway Nicola Deidre PetalChief Human Resources Officer | Sale | −13.0K | $18.11 | $235K | Aug 18, 2026 | Form 4 ↗ |
| Shannon Elaine MaryPres., Global Supply & Quality | Sale | −20.4K | $17.55 | $357K | Aug 11, 2026 | Form 4 ↗ |
| Farajallah Awny Samaan BotrosChief Medical Officer | Sale | −14.0K | $17.10 | $240K | Aug 10, 2026 | Form 4 ↗ |
| Ibrahim Ramy Riad AhmedPresident, PDT BU | Sale | −7,277 | $17.10 | $124K | Aug 10, 2026 | Form 4 ↗ |
| Pacheco Rhonda JanicePresident, U.S. Business Unit | Sale | −16.9K | $17.10 | $289K | Aug 10, 2026 | Form 4 ↗ |
| Duprey Lauren RusckowskiChief Transformation Officer | Sale | −47.6K | $17.10 | $814K | Aug 10, 2026 | Form 4 ↗ |
| Plump Andrew StewartPresident, R&D · Director | Sale | −165.4K | $17.10 | $2.8M | Aug 10, 2026 | Form 4 ↗ |
| Pignagnoli Agosti MarcelloHead, Strat. & Port. Dev | Sale | −23.0K | $17.10 | $393K | Aug 10, 2026 | Form 4 ↗ |
| Bitetti Teresa MariePresident, OBU | Sale | −50.0K | $17.10 | $855K | Aug 10, 2026 | Form 4 ↗ |
| Shannon Elaine MaryPres., Global Supply & Quality | Sale | −3,978 | $17.10 | $68K | Aug 10, 2026 | Form 4 ↗ |
| Ricci GabrieleChief Data & Tech. Officer | Sale | −25.1K | $17.10 | $429K | Aug 10, 2026 | Form 4 ↗ |
| Greenway Nicola Deidre PetalChief Human Resources Officer | Sale | −6,774 | $17.10 | $116K | Aug 10, 2026 | Form 4 ↗ |
| Kim Julie So-YoungPresident and CEO · Director | Sale | −89.1K | $17.10 | $1.5M | Aug 10, 2026 | Form 4 ↗ |
| Platford Giles RichardPresident, IBU | Sale | −31.1K | $17.10 | $532K | Aug 10, 2026 | Form 4 ↗ |
| Furney Natalie Anne MarieGlobal General Counsel | Sale | −30.9K | $17.10 | $528K | Aug 10, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding TAK · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| American Mutual Fund | 18.2M | $310.3M | 0.26% | Jul 31, 2026 |
| Capital Income Builder | 7.3M | $125.5M | 0.10% | Jul 31, 2026 |
| First Trust Value Line Dividend Index Fund First Trust Exchange-Traded Fund | 2.0M | $32.5M | 0.40% | Jun 30, 2026 |
| VanEck Pharmaceutical ETF VanEck ETF Trust | 1.5M | $27.7M | 2.71% | Sep 30, 2026 |
| Steward Values Enhanced International Fund Steward Funds Inc | 711.9K | $12.2M | 3.58% | Jul 31, 2026 |
| Avantis International Equity ETF American Century ETF Trust | 553.0K | $9.9M | 0.05% | Aug 31, 2026 |
| Mercer Non-US Core Equity Fund Mercer Funds | 513.8K | $9.3M | 0.20% | Sep 30, 2026 |
| Goldman Sachs Income Builder Fund GOLDMAN SACHS TRUST | 494.4K | $8.5M | 0.30% | Jul 31, 2026 |
| ActivePassive International Equity ETF Trust for Professional Managers | 168.3K | $3.0M | 0.26% | Aug 31, 2026 |
| Catalyst/MAP Global Equity Fund MUTUAL FUND SERIES TRUST | 169.0K | $2.7M | 2.84% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list TAK's shares (CUSIP 874060205), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
No 13D/13G beneficial-ownership filings on record.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming takeda pharmaceuticals as client
- AVENUE SOLUTIONSTAKEDA PHARMACEUTICALS AMERICA, INC. · 2026 Q3 · HCR$50K
Filing ↗ - FARRAGUT PARTNERS LLPTAKEDA PHARMACEUTICALS AMERICA INC · 2026 Q3 · HCR$50K
Filing ↗ - TAKEDA PHARMACEUTICALS AMERICA, INC.TAKEDA PHARMACEUTICALS AMERICA INC · 2026 Q3 · MMM, HCR, TAX, TRD$1.4M
Filing ↗ - TIBER CREEK GROUPTAKEDA PHARMACEUTICALS AMERICA, INC. · 2026 Q3 · MMM$50K
Filing ↗ - TODD STRATEGY GROUPTAKEDA PHARMACEUTICALS AMERICA, INC. · 2026 Q3 · HCR, MMM, TRD$50K
Filing ↗
Government Contracts
Federal awards to takeda pharmaceuticals · USAspending
$1.5MAwarded · 17 contracts on record
- Department of JusticeFY27 PHARMACY TAKEDA$371K
Oct 1, 2026 · ↗ - Department of Veterans AffairsGAMMAGARD LIQUID ERC - GLOBULIN,IMMUNE (IV) 10% INJ$25K
Apr 27, 2026 · ↗ - Department of Veterans AffairsGAMMAGARD$58K
Oct 1, 2026 · ↗ - Department of Veterans AffairsLANADELUMAB-FLYO 150MG/ML INJ, SYRINGE,2ML (TAKHZYRO)$193K
May 20, 2024 · ↗ - Department of Veterans AffairsTAKHZYRO 150 MG$38K
Aug 27, 2026 · ↗ - Department of Veterans AffairsTAKHZYRO 150 MG$0
Aug 27, 2026 · ↗ - Department of JusticeFY26 PHARMACEUTICALS TAKEDA APRIL-SEPTEMBER$551K
Apr 1, 2026 · ↗ - Department of Veterans AffairsLIVTENCITY 200 MG$19K
Aug 28, 2026 · ↗
U.S. Patents
Recent USPTO applications naming TAKEDA PHARMACEUTICAL CO LTD
No USPTO patent applications found for TAKEDA PHARMACEUTICAL CO LTD.
Annual Financials
From TAK's 10-K filings · XBRL
SEC's XBRL figures for TAKEDA PHARMACEUTICAL CO LTD include no full-year results from a 10-K in US dollars, so there is no table to show. Companies based abroad usually report annually on Form 20-F instead.
Stock Splits
Every split and reverse split in the price history
No stock splits in TAK's price history.
Material Events (8-K)
Corporate events filed with the SEC
No 8-K filings on record.
About TAKEDA PHARMACEUTICAL CO LTD
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersTOKYO, Japan
SEC CIK0001395064 ↗








